Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension-Reference-Cited by-同舟云学术

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension

Published:2013-08-05 Issue:12 Volume:73 Page:2094-2100
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Keystone Edward,Landewé Robert,van Vollenhoven Ronald,Combe Bernard,Strand Vibeke,Mease Philip,Shaughnessy Laura,VanLunen Brenda,van der Heijde Désirée

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study;Modern Rheumatology;2024-03-29

2. Certolizumab pegol in severe rheumatoid arthritis: Real-world evidence in an Argentine cohort: Achievement of targets (T2T) at 3 months and predictive factors.;Global Rheumatology;2024-02-22

3. Certolizumab pegol na artrite reumatoide severa: Evidência do mundo real em uma coorte argentina: Alcance de objetivos (T2T) em 3 meses e fatores preditivos.;Global Rheumatology;2024-02-22

4. Certolizumab pegol en artritis reumatoidea severa. Evidencia de la vida real en una cohorte argentina: Logro de objetivos (T2T) a 3 meses y factores predictivos.;Global Rheumatology;2024-02-22

5. Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project;Pharmacological Research;2024-02